drugset / Trial / NCT07650084
A 24-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough - China Extension
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This is a randomized, double-blind, placebo-controlled, parallel-arm, Phase 3 study of BLU-5937 in participants with Refractory Chronic Cough (RCC).
Timeline
- Start
- 2025-11-21
- Primary completion
- 2027-08-27
- Completion
- 2028-06-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Camlipixant | Small molecule | 25 mg | Oral |
| Subject | Camlipixant | Small molecule | 50 mg | Oral |